Skip to main content
Erschienen in: Breast Cancer 6/2014

01.11.2014 | Original Article

Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer

verfasst von: Natsue Uehiro, Rie Horii, Takuji Iwase, Masahiko Tanabe, Takehiko Sakai, Hidetomo Morizono, Kiyomi Kimura, Kotaro Iijima, Yumi Miyagi, Seiichiro Nishimura, Masujiro Makita, Yoshinori Ito, Futoshi Akiyama

Erschienen in: Breast Cancer | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

The TNM classification of the Unio Internationalis Contra Cancrum was revised for the seventh edition. The major change concerning breast cancer is a change in the stages for patients with T0 or T1N1miM0. In the present study, the seventh edition of the TNM classification was validated in breast cancer.

Methods

The stages of 416 breast cancer patients, treated at our hospital in 1996, were classified according to the TNM classification, sixth and seventh editions, and their prognoses were compared.

Results

Case distribution using the sixth edition was stage 0, 56 cases (13.5 %); stage I, 158 cases (38.0 %); stage II, 130 [A, 102; B, 28] cases (31.2 [A, 24.5; B, 6.7] %); and stage III, 72 [A, 31; B, 8; C, 33] cases (17.3 [A, 7.5; B, 1.9; C, 7.9] %). According to the seventh edition, the stages for 20 patients, accounting for 19.6 % of IIA cases according to the sixth edition, decreased from IIA to IB. The 10-year overall survivals were stage 0, 91.1 %; stage I, 88.6 %; stage II, 80.8 %; and stage III, 63.9 % according to the sixth edition; and stage 0, 91.1 %; stage I, 88.8 %; stage II, 79.1 %; and stage III, 63.9 % according to the seventh edition. Although no significant differences were seen among the survival rates for stages 0 to II according to the sixth edition, there was a significant difference between stage I and II according to the seventh edition (p = 0.026).

Conclusion

The latest revision of the TNM classification is appropriate for breast cancer from the perspective of prognosis.
Literatur
1.
Zurück zum Zitat Greene FL. Breast tumours. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009. p. 181–93. Greene FL. Breast tumours. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009. p. 181–93.
2.
Zurück zum Zitat Greene FL. Breast tumours. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002. p. 131–141. Greene FL. Breast tumours. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002. p. 131–141.
3.
Zurück zum Zitat Patani N, Mokbel K. Clinical significance of sentinel lymph node isolated tumour cells in breast cancer. Breast Cancer Res Treat. 2011;127:325–34.PubMedCrossRef Patani N, Mokbel K. Clinical significance of sentinel lymph node isolated tumour cells in breast cancer. Breast Cancer Res Treat. 2011;127:325–34.PubMedCrossRef
4.
Zurück zum Zitat de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410–25.PubMedCrossRef de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst. 2010;102:410–25.PubMedCrossRef
5.
Zurück zum Zitat Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol. 2007;14:3378–84.PubMedCrossRef Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol. 2007;14:3378–84.PubMedCrossRef
6.
Zurück zum Zitat Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333–40.PubMedCrossRef Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg. 2009;208:333–40.PubMedCrossRef
7.
Zurück zum Zitat Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803–9.PubMedCrossRef Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol. 2008;26:1803–9.PubMedCrossRef
8.
Zurück zum Zitat Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol. 2009;16:113–20.PubMedCrossRef Pugliese MS, Beatty JD, Tickman RJ, Allison KH, Atwood MK, Szymonifka J, et al. Impact and outcomes of routine microstaging of sentinel lymph nodes in breast cancer: significance of the pN0(i+) and pN1mi categories. Ann Surg Oncol. 2009;16:113–20.PubMedCrossRef
9.
Zurück zum Zitat Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCrossRefPubMedCentral Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCrossRefPubMedCentral
10.
Zurück zum Zitat Giuliano AE, Dale PS, Turner RR, Morton DL, Evance SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401.PubMedCrossRefPubMedCentral Giuliano AE, Dale PS, Turner RR, Morton DL, Evance SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394–401.PubMedCrossRefPubMedCentral
11.
Zurück zum Zitat Salhab M, Patani N, Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol. 2011;20:e195–206.PubMedCrossRef Salhab M, Patani N, Mokbel K. Sentinel lymph node micrometastasis in human breast cancer: an update. Surg Oncol. 2011;20:e195–206.PubMedCrossRef
12.
Zurück zum Zitat Park D, Káresen R, Naume B, Synnesvedt M, Beraki E, Sauer T. The prognostic impact of occult nodal metastasis in early breast carcinoma. Breast Cancer Res Treat. 2009;118:57–66.PubMedCrossRef Park D, Káresen R, Naume B, Synnesvedt M, Beraki E, Sauer T. The prognostic impact of occult nodal metastasis in early breast carcinoma. Breast Cancer Res Treat. 2009;118:57–66.PubMedCrossRef
13.
Zurück zum Zitat Grabau D, Ryden L, Femö M, Ingvar C. Analysis of sentinel node biopsy—a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols. Histopathology. 2011;59:129–38.PubMedCrossRef Grabau D, Ryden L, Femö M, Ingvar C. Analysis of sentinel node biopsy—a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols. Histopathology. 2011;59:129–38.PubMedCrossRef
14.
Zurück zum Zitat Rydén L, Chebil G, Sjöström L, Pawlowski R, Jönsson PE. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol. 2007;33:33–8.PubMedCrossRef Rydén L, Chebil G, Sjöström L, Pawlowski R, Jönsson PE. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy. Eur J Surg Oncol. 2007;33:33–8.PubMedCrossRef
15.
Zurück zum Zitat Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354:896–900.PubMedCrossRef Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354:896–900.PubMedCrossRef
16.
Zurück zum Zitat Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807–16.PubMedCrossRef Tsujimoto M, Nakabayashi K, Yoshidome K, Kaneko T, Iwase T, Akiyama F, et al. One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res. 2007;13:4807–16.PubMedCrossRef
Metadaten
Titel
Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer
verfasst von
Natsue Uehiro
Rie Horii
Takuji Iwase
Masahiko Tanabe
Takehiko Sakai
Hidetomo Morizono
Kiyomi Kimura
Kotaro Iijima
Yumi Miyagi
Seiichiro Nishimura
Masujiro Makita
Yoshinori Ito
Futoshi Akiyama
Publikationsdatum
01.11.2014
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 6/2014
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-013-0453-7

Weitere Artikel der Ausgabe 6/2014

Breast Cancer 6/2014 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.